Related Experiment Video
Updated: May 3, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Dabrafenib for treatment of BRAF-mutant melanoma
Radhika Kainthla1, Kevin B Kim2, Gerald S Falchook3
1Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA.
Abstract:
Melanoma has the highest mortality of all the skin cancer subtypes. Historically, chemotherapy and immunologic therapies have yielded only modest results in the treatment of metastatic melanoma. The discovery of prevalent V600 BRAF mutations driving proliferation makes this oncogenic protein an ideal target for therapy. Dabrafenib, a reversible inhibitor of mutant BRAF kinase, improved response rates and median progression-free survival in patients with V600E BRAF-mutant metastatic melanoma, including those with brain metastases. With a well-tolerated toxicity profile, dabrafenib is effective as a monotherapy; however, resistance eventually develops in almost all patients. As a result, current research is exploring the role of combination therapies with dabrafenib to overcome resistance.
Insights
Dabrafenib effectively treats BRAF-mutant melanoma, including brain metastases. However, resistance develops, prompting research into combination therapies for advanced melanoma.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Melanoma is the deadliest skin cancer subtype.
- Metastatic melanoma treatment historically showed limited efficacy.
- V600 BRAF mutations are key drivers of melanoma proliferation.
Purpose of the Study:
- To evaluate dabrafenib, a BRAF kinase inhibitor, for V600E BRAF-mutant metastatic melanoma.
- To assess dabrafenib's efficacy, safety, and role in overcoming resistance.
Main Methods:
- Clinical trials assessing dabrafenib monotherapy.
- Analysis of response rates and progression-free survival.
- Investigation of resistance mechanisms and combination therapies.
Main Results:
- Dabrafenib improved response rates and progression-free survival in V600E BRAF-mutant metastatic melanoma.
- Efficacy was observed even in patients with brain metastases.
- Dabrafenib demonstrated a well-tolerated toxicity profile.
Conclusions:
- Dabrafenib is an effective monotherapy for BRAF-mutant metastatic melanoma.
- Acquired resistance to dabrafenib is a significant clinical challenge.
- Combination therapies are crucial for overcoming dabrafenib resistance and improving long-term outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...